By Clinical Research Staff 

February 3, 2026 | An assortment of new product launches, funding news, and leadership appointments were announced in conjunction with this week’s SCOPE event in Orlando, which is experiencing a record-breaking attendance exceeding 4,800 people. The announcements serve as a potent reminder that artificial intelligence (AI) is having a field day in clinical research, and the common aim is right sizing the time and cost of getting medicines to market. 

ConcertAI unveiled Accelerated Clinical Trials (ACT), an enterprise agentic AI platform designed to automate and inject predictive intelligence into the overall study process. It integrates real-world and proprietary data with advanced AI workflows to help sponsors and contract research organizations (CROs) shorten trial timelines by 10 to 20 months and dramatically reduce costs. 

ACT is built on CARAai, the company’s multimodal agentic AI platform, and deploys a suite of purpose-built assistants and agents to automate critical trial activities such as literature reviews, protocol design, competitive trial analysis, feasibility assessments, site selection, and patient matching. Development teams can use its design and writing tools to slash design timelines and costly protocol amendments by 50%. The platform’s automated validation strategies can also reduce timelines related to site selection, activation, and recruitment by 25% to 50%. 

PhaseV launched its AI-powered Enrollment Lab solution, an additional layer to its ClinOps platform, enabling sponsors to quantify a study's enrollment potential and model the impact of constraints and trade-offs prior to site identification. The company’s population-first approach looks to accelerate traditional site-level surveys with electronic health records data for real-time modeling of enrollment dynamics. 

Study teams can use Enrollment Lab to explore alternatives and evaluate how specific inclusion and exclusion criteria impact patient volume. The goal is to help them optimize design and identify high-opportunity geographic regions and patient segments. 

Meanwhile, Barcelona-based AI company Biorce announced it has closed a $52.5 million Series A round. The financing includes new investment from DST Global Partners, with existing investors Norrsken VC and YZR Capital increasing their participation, alongside participation from Mustard Seed Maze and Endeavor Catalyst. Among the prominent angel investors in the round are Nik Storonsky, CEO of Revolut; Arthur Mensch, co-founder and CEO of Mistral AI; Paulo Rosado, founder of OutSystems; Albert Nieto, founder of Seedtag; Stef Van Grieken, co-founder of Cradle; and Alex Berriche, founder of Fleet. 

The mission of Biorce is to make clinical trials faster, as well as more reliable and accessible, on a global scale. Its Aika platform is built on a data foundation of 1 million clinical trials and designed to anticipate risks, reduce errors, and eliminate protocol amendments to accelerate the development of new therapies by up to 50%.  

Wait, There’s More ... 

In the leadup to SCOPE, several companies also broke news about the products that would be showcased and people who would be shaking hands at the conference. First up was WCG regarding the unveiling of ClinSphere Trial IntelX, its next-generation predictive intelligence solution powered by more than 80,000 complete protocols and 40,000 operationally benchmarked trials, to aid sponsors and CROs in the planning, designing, and execution of clinical trials. 

Key features of the tool include agentic AI for enrollment and performance forecasting, scoring of participant and site burden, enrollment forecasting and operational risk alerts supporting adaptive methodologies, explainable AI coupled with WCG expert review, and a portfolio optimization module. Syneos Health was also revealed as the first customer to adopt Trial IntelX. 

Medable announced the launch of its third agentic AI agent, this time for helping research sites reduce burden and assisting principal investigators (PIs) in the oversight and monitoring of electronic clinical outcome assessment (eCOA) data. The company previously released agents for automating trial master file processes and clinical trial monitoring, and all three are part of its Agent Studio platform purpose-built for life sciences.  

The new PI Summary Agent integrates seamlessly within Medable’s eCOA system workflows and is intended to make remote oversight seamless. It provides a participant summary highlighting the most critical data points and surfacing critical patient data for timely review. 

IgniteData additionally announced two appointments to its senior leadership team—Laura Hilty as chief strategy officer and Joe Lengfellner as chief product officer—and they both bring with them a proven track record of building and scaling impactful technology solutions. Hilty’s leadership background spans corporate strategy, corporate development, product management, and partnerships for companies of every size, including leading firms like Advarra, Forte Research Systems, and Epic. She is also a principal at HealthX Ventures, an investor in IgniteData. Lengfellner joins the company after more than 15 years at the forefront of deploying technologies at Memorial Sloan Kettering Cancer Center. In this most recent role there, he led a large team of digital health and information technology professionals supporting the organization’s global clinical research portfolio.